HK1107526A1 - Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis - Google Patents

Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

Info

Publication number
HK1107526A1
HK1107526A1 HK08100214.2A HK08100214A HK1107526A1 HK 1107526 A1 HK1107526 A1 HK 1107526A1 HK 08100214 A HK08100214 A HK 08100214A HK 1107526 A1 HK1107526 A1 HK 1107526A1
Authority
HK
Hong Kong
Prior art keywords
gna1870
protection against
diseases caused
broad spectrum
neisseria meningitidis
Prior art date
Application number
HK08100214.2A
Other languages
English (en)
Inventor
Dan M Granoff
Victor Hou
Original Assignee
Childrens Hosp & Res Ct Oak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp & Res Ct Oak filed Critical Childrens Hosp & Res Ct Oak
Publication of HK1107526A1 publication Critical patent/HK1107526A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK08100214.2A 2005-01-27 2008-01-08 Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis HK1107526A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64791105P 2005-01-27 2005-01-27
PCT/US2006/002523 WO2006081259A2 (fr) 2005-01-27 2006-01-23 Vaccins vesiculaires a base de gna1870 conferant une protection a large spectre contre les maladies provoquees par neisseria meningitidis

Publications (1)

Publication Number Publication Date
HK1107526A1 true HK1107526A1 (en) 2008-04-11

Family

ID=36741009

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08100214.2A HK1107526A1 (en) 2005-01-27 2008-01-08 Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

Country Status (20)

Country Link
US (7) US9034345B2 (fr)
EP (3) EP2682126B1 (fr)
JP (1) JP4993750B2 (fr)
CN (1) CN101107007B (fr)
AU (1) AU2006208208B2 (fr)
BR (1) BRPI0607374B8 (fr)
CA (1) CA2590974C (fr)
CY (1) CY1118732T1 (fr)
DK (1) DK2682126T3 (fr)
ES (1) ES2616294T3 (fr)
HK (1) HK1107526A1 (fr)
HU (1) HUE033196T2 (fr)
LT (1) LT2682126T (fr)
MX (1) MX2007008785A (fr)
NZ (1) NZ555937A (fr)
PL (1) PL2682126T3 (fr)
PT (1) PT2682126T (fr)
RU (1) RU2432962C2 (fr)
SI (1) SI2682126T1 (fr)
WO (1) WO2006081259A2 (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU761780B2 (en) 1998-05-01 2003-06-12 Glaxosmithkline Biologicals Sa Neisseria meningitidis antigens and compositions
MXPA01011867A (es) 1999-05-19 2002-05-06 Chiron Spa Composiciones neisseriales de combinacion.
AU784203B2 (en) 1999-10-29 2006-02-23 Glaxosmithkline Biologicals S.A. Neisserial antigenic peptides
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP2275129A3 (fr) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Vaccin omv complèté contre la méningocoque
JP4763210B2 (ja) 2000-02-28 2011-08-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ナイセリアのタンパク質の異種発現
EP1322328B1 (fr) * 2000-07-27 2014-08-20 Children's Hospital & Research Center at Oakland Vaccins pour protection a large spectre contre les maladies causees par neisseria meningitidis
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
RU2432962C2 (ru) 2005-01-27 2011-11-10 Чилдрен'З Хоспитал Энд Рисерч Сентер Эт Окленд Вакцины с использованием везикул на основе gna 1870 широкого спектра действия для профилактики заболеваний, вызываемых neisseria meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US20090035328A1 (en) * 2007-08-02 2009-02-05 Dan Granoff fHbp- AND LPXL1-BASED VESICLE VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS
EP2039764A1 (fr) * 2007-09-19 2009-03-25 Pevion Biotech AG Protéinase aspartyl à sécrétoire tronqué 2
CN101951949B (zh) 2007-10-19 2013-10-02 诺华股份有限公司 脑膜炎球菌疫苗制剂
EP3263591B1 (fr) 2008-02-21 2019-03-27 GlaxoSmithKline Biologicals S.A. Polypeptides fhbp méningococciques
NZ588191A (en) 2008-03-03 2012-06-29 Irm Llc Compounds and compositions as tlr activity modulators
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
JP5723768B2 (ja) 2008-05-30 2015-05-27 ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー オブ ジ アーミー， オン ビハーフ オブ ウォルター リード アーミー インスティチュート オブ リサーチ 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用
CA2733943A1 (fr) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presentant un epitope d'un domaine a de proteine de liaison au facteur h et procedes d'utilisation
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
AU2015275311B2 (en) * 2008-10-25 2017-07-13 Imperial Innovations Limited Vaccine compositions comprising a mutated factor h binding protein
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
WO2010070453A2 (fr) 2008-12-17 2010-06-24 Novartis Ag Vaccins méningococciques comprenant un récepteur de l'hémoglobine
CN102438649A (zh) * 2009-03-24 2012-05-02 诺华有限公司 脑膜炎球菌h因子结合蛋白和肺炎球菌结合糖的组合物
PT2411048T (pt) 2009-03-24 2020-07-14 Glaxosmithkline Biologicals Sa Proteína de ligação ao fator h meningocócica com adjuvante
NZ595361A (en) * 2009-04-30 2013-09-27 Childrens Hosp & Res Ct Oak Chimeric factor h binding proteins (fhbp) and methods of use
WO2010144734A1 (fr) 2009-06-10 2010-12-16 Novartis Ag Vaccins contenant de la benzonaphtyridine
EP2470204B1 (fr) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Polypeptides hybrides contenant des séquences fhbp à méningocoques
WO2011024071A1 (fr) 2009-08-27 2011-03-03 Novartis Ag Adjuvant contenant de l'aluminium, un oligonucléotide et une polycation
WO2011027971A2 (fr) * 2009-09-01 2011-03-10 주식회사이언메딕스 Vésicules extracellulaires dérivées de la flore intestinale, et procédé de recherche d'un modèle de maladie, d'un vaccin et d'un médicament candidat, et de diagnostic utilisant ce dernier
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
AU2010302344A1 (en) * 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
MX2012004850A (es) 2009-10-27 2012-05-22 Novartis Ag Polipeptidos fhbp meningococicos modificados.
WO2011057148A1 (fr) 2009-11-05 2011-05-12 Irm Llc Composés et compositions permettant de moduler l'activité des tlr-7
AU2010315115B2 (en) 2009-11-06 2015-01-29 Children's Hospital & Research Center At Oakland T-cell stimulating protein B and methods of use
CN102762206A (zh) 2009-12-15 2012-10-31 诺华有限公司 免疫增强化合物的均匀悬液及其用途
CN103002910A (zh) * 2010-03-10 2013-03-27 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
EP2547357A1 (fr) 2010-03-18 2013-01-23 Novartis AG Vaccins adjuvantés contre le méningocoque de sérogroupe b
EA023725B1 (ru) 2010-03-23 2016-07-29 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
CA2790167C (fr) * 2010-03-30 2021-02-09 Children's Hospital & Research Center Oakland Proteines de liaison du facteur h (fhbp) avec des proprietes alterees et leurs procedes d'utilisation
EP2585106A1 (fr) 2010-06-25 2013-05-01 Novartis AG Associations de protéines de liaison du facteur h méningococcique
JP5814363B2 (ja) * 2010-07-01 2015-11-17 イオン メディックス インコーポレイテッド 細胞の原形質体に由来するマイクロベシクル及びその用途
MX350142B (es) 2010-08-23 2017-08-28 Wyeth Llc * Formulaciones estables de antigenos rlp2086 de neisseria meningitidis.
EP3549601B1 (fr) 2010-09-10 2021-02-24 Wyeth LLC Dérivés non-lipidés des antigènes orf2086 de neisseria meningitidis
WO2012032498A2 (fr) 2010-09-10 2012-03-15 Novartis Ag Développements apportés à des vésicules membranaires externes méningococciques
EP2707009A1 (fr) 2011-05-12 2014-03-19 Novartis AG Antipyrétiques pour améliorer la tolérabilité de vaccins à base de vésicules
CA2840096C (fr) * 2011-07-07 2021-07-06 Bas VAN DE WATERBEEMD Procede pour la production sans detergent de vesicules a membrane externe
AU2013214105A1 (en) * 2012-02-02 2014-07-24 Novartis Ag Promoters for increased protein expression in meningococcus
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
JP2015524418A (ja) 2012-07-27 2015-08-24 アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 血管内皮細胞への髄膜炎菌の線毛媒介接着の受容体としてのｃｄ１４７
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
MX363529B (es) 2012-09-18 2019-03-27 Novartis Ag Vesículas de membrana externa.
CA2900454A1 (fr) 2013-02-07 2014-08-14 Glaxosmithkline Biologicals Sa Compositions pharmaceutiques contenant des vesicules
EP2964665B1 (fr) 2013-03-08 2018-08-01 Pfizer Inc Polypeptides immunogènes de fusion
SG11201600334SA (en) 2013-08-02 2016-02-26 Children S Hospital & Res Ct Oakland Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
KR20160127104A (ko) 2014-02-28 2016-11-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 수막구균 fhbp 폴리펩티드
EP4074726A3 (fr) 2014-07-23 2022-11-23 Children's Hospital & Research Center at Oakland Variants de protéines de liaison au facteur h et leurs procédés d'utilisation
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
WO2019018744A1 (fr) 2017-07-21 2019-01-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions immunogènes de neisseria meningitidis
EP3607967A1 (fr) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Polypeptides modifiés du méningocoque fhbp

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
IL84285A (en) 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5001065A (en) 1987-05-27 1991-03-19 Cetus Corporation Human cell line and triomas, antibodies, and transformants derived therefrom
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5231026A (en) 1987-12-31 1993-07-27 Tanox Biosystems, Inc. DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
US5292867A (en) 1988-11-16 1994-03-08 Tanox Biosystems, Inc. Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin
ATE120093T1 (de) 1988-12-19 1995-04-15 Praxis Biolog Inc Meningococcales klasse i-aussenmembranprotein- vakzin.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
IL94872A (en) 1989-06-30 1995-03-30 Oncogen Monoclonal or chimeric antibodies that react with human carcinoma, recombinant proteins that contain their anti-binding site, pharmaceutical preparations and kits that contain the
US5075431A (en) 1989-07-26 1991-12-24 City Of Hope Chimeric anti-CEA antibody
US5081235A (en) 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
ES2108278T3 (es) 1992-06-25 1997-12-16 Smithkline Beecham Biolog Composicion de vacuna con coadyuvantes.
NL9201716A (nl) * 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
US5472693A (en) 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
WO1994021292A1 (fr) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Compositions vaccinales renfermant le lipide a monophosphorylique 3-o desacetyle
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE328890T1 (de) 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) * 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
EP1537877A3 (fr) 1996-10-11 2005-08-03 The Regents Of The University Of California Conjugués polynucléotides immunostimulateurs/molécule immunomodulatrice
EP1039935A4 (fr) 1997-02-28 2005-04-27 Univ Iowa Res Found UTILISATION D'ACIDES NUCLEIQUES CONTENANT DES DINUCLEOTIDES CpG NON METHYLES DANS LE TRAITEMENT DES TROUBLES ASSOCIES AUX LIPOPOLYSACCHARIDES
EP1005368B1 (fr) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Utilisation d'acides nucléiques contenat un dinucléotide CpG non-methylé combiné avec de l'aluminium en tant qu'adjuvants
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
ATE252596T1 (de) 1997-06-06 2003-11-15 Dynavax Tech Corp Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1009382B1 (fr) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Emulsions huile-dans-l'eau contenant des saponines
CA2308606A1 (fr) 1997-11-06 1999-05-20 Chiron S.P.A. Antigenes de neisseria
EP2278011A3 (fr) 1998-01-14 2012-03-07 Novartis Vaccines and Diagnostics S.r.l. Antigène de neisseria meningitidis
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
AU761780B2 (en) 1998-05-01 2003-06-12 Glaxosmithkline Biologicals Sa Neisseria meningitidis antigens and compositions
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
MXPA01003557A (es) 1998-10-09 2004-04-05 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
EP2266604A3 (fr) 1998-10-16 2011-05-11 GlaxoSmithKline Biologicals S.A. Produits adjuvants et vaccins
US20030215469A1 (en) 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
EP1127137B2 (fr) 1998-11-03 2013-12-25 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Lps a toxicite reduite obtenu a partir de bacteries a gram negatif
US7081244B2 (en) 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
DE60038166T2 (de) 1999-03-19 2009-03-12 Glaxosmithkline Biologicals S.A., Rixensart Impfstoff gegen bakterielle antigene
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
AU780308B2 (en) 1999-04-30 2005-03-17 J. Craig Venter Institute, Inc. Neisseria genomic sequences and methods of their use
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
CA2383413A1 (fr) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Vaccins
PL355232A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
WO2001034642A2 (fr) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Commande de la synthese de membrane de neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP2275129A3 (fr) * 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Vaccin omv complèté contre la méningocoque
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
EP1322328B1 (fr) * 2000-07-27 2014-08-20 Children's Hospital & Research Center at Oakland Vaccins pour protection a large spectre contre les maladies causees par neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0024200D0 (en) 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
GB0103169D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US6839862B2 (en) 2001-05-31 2005-01-04 Koninklijke Philips Electronics N.V. Parallel data communication having skew intolerant data groups
ATE469915T1 (de) 2001-07-27 2010-06-15 Novartis Vaccines & Diagnostic Antikörper gegen das meningokokken adhäsin app
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
EP1374892A1 (fr) 2002-06-28 2004-01-02 Braun, Jan Matthias, Dr. Médicament pour le traitement des maladies causées par une infection de neisseria meningitidis
EP2255826B1 (fr) 2002-08-02 2016-04-13 GlaxoSmithKline Biologicals S.A. Composition vaccinale comprenant une combinaison d'antigenes de neisseria
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
PT2353608T (pt) 2002-10-11 2020-03-11 Novartis Vaccines And Diagnostics S R L Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
RU2432962C2 (ru) * 2005-01-27 2011-11-10 Чилдрен'З Хоспитал Энд Рисерч Сентер Эт Окленд Вакцины с использованием везикул на основе gna 1870 широкого спектра действия для профилактики заболеваний, вызываемых neisseria meningitidis
US20090035328A1 (en) * 2007-08-02 2009-02-05 Dan Granoff fHbp- AND LPXL1-BASED VESICLE VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS
CN102203276A (zh) * 2008-08-27 2011-09-28 奥克兰儿童医院及研究中心 基于补体因子h对脑膜炎奈瑟球菌血清杀菌活性的鉴定

Also Published As

Publication number Publication date
US20120093867A1 (en) 2012-04-19
PT2682126T (pt) 2017-02-28
EP2433647A2 (fr) 2012-03-28
AU2006208208A1 (en) 2006-08-03
CA2590974A1 (fr) 2006-08-03
EP2433647A3 (fr) 2012-06-06
US10046043B2 (en) 2018-08-14
EP1855715B1 (fr) 2013-03-13
CN101107007A (zh) 2008-01-16
MX2007008785A (es) 2008-02-15
US20180369356A1 (en) 2018-12-27
HUE033196T2 (en) 2017-11-28
US20150290312A1 (en) 2015-10-15
RU2432962C2 (ru) 2011-11-10
US8968748B2 (en) 2015-03-03
AU2006208208B2 (en) 2011-05-19
US9034345B2 (en) 2015-05-19
JP4993750B2 (ja) 2012-08-08
WO2006081259A2 (fr) 2006-08-03
EP1855715A4 (fr) 2009-06-17
US20210308247A1 (en) 2021-10-07
RU2007128332A (ru) 2009-01-27
CA2590974C (fr) 2017-10-03
CY1118732T1 (el) 2017-07-12
EP2682126B1 (fr) 2016-11-23
JP2008528597A (ja) 2008-07-31
EP1855715A2 (fr) 2007-11-21
PL2682126T3 (pl) 2017-07-31
ES2616294T3 (es) 2017-06-12
SI2682126T1 (sl) 2017-03-31
CN101107007B (zh) 2011-08-17
US20080248065A1 (en) 2008-10-09
BRPI0607374B8 (pt) 2021-05-25
BRPI0607374B1 (pt) 2020-04-22
US11801293B2 (en) 2023-10-31
US10478484B2 (en) 2019-11-19
LT2682126T (lt) 2017-02-27
BRPI0607374A2 (pt) 2009-09-01
US10857221B2 (en) 2020-12-08
US20170065699A1 (en) 2017-03-09
NZ555937A (en) 2009-05-31
US9452208B2 (en) 2016-09-27
DK2682126T3 (en) 2017-02-27
EP2682126A1 (fr) 2014-01-08
US20200138931A1 (en) 2020-05-07
WO2006081259A3 (fr) 2007-03-01

Similar Documents

Publication Publication Date Title
HK1107526A1 (en) Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
EP2185576A4 (fr) Vaccins vésiculaires à base de fhbp et de lpxl1 pour une protection à large spectre contre les maladies à neisseria meningitidis
EP1322328A4 (fr) Vaccins pour protection a large spectre contre les maladies causees par neisseria meningitidis
ZA200710558B (en) Immunogens for meningitidis-a vaccines
HK1128593A1 (en) A composition suitable for ophthalmic administration
ZA200804918B (en) Therapeutic vaccine
IL192084A0 (en) Vaccine
GB0504436D0 (en) Vaccine
ZA200609105B (en) Vaccine for periodontal disease
GB0419846D0 (en) Vaccine adjuvants for saccharides
EP1866326A4 (fr) Immunogenes pour vaccins contre des pathogenes et maladies a antigenicite variable
GB0515135D0 (en) Vaccine
ZA200709207B (en) Vaccine
GB0516944D0 (en) Vaccine
HK1190343A1 (zh) 對腦膜炎奈瑟氏菌所致疾病具有廣譜保護作用的 囊泡疫苗
GB0810662D0 (en) Vaccine
ZA200709210B (en) Vaccine
EP1927353A4 (fr) Médicament contre les maladies cornéennes
GB0526412D0 (en) Vaccine
GB0409133D0 (en) Methods for preparing pharmaceutical compositions
IL190453A0 (en) Methods for crop protection
GB0513194D0 (en) Vaccine
GB0513191D0 (en) Vaccine
GB0521164D0 (en) Vaccine
GB0523445D0 (en) Vaccine

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: CORRECTED DATA OF SECTION 27 TO JOURNAL OF 20130719: (54)